WarkentinTE, GreinacherA, KosterA, LincoffAM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest2008; 133:340S–80S. DOI 10.1378/chest.08-0677
2.
Package insert. Argatroban. Research Triangle Park, NC: GlaxoSmithKline, March2009.
3.
BatesSM, WeitzJI, JohnstonM, HirschJ, GinsbergJS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med2001; 161:385–91. DOI 10.1001/archinte.1613.385
4.
GosselinRC, KingJH, JanatpourKA. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother2004; 38:1383–8. DOI 10.1345/aph.1D565
5.
NadlerSB, HidalgoJU, BlochT. Prediction of blood volume in normal human adults. Surgery1962; 51:224–32.
6.
SkrupkyLP, SmithJR, DealEN. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy2010; 30:1229–38.
